These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22852027)

  • 21. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
    Courtney KD; Taplin ME
    Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C; Mourey L; Pouessel D; Ploussard G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
    Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
    Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
    Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.
    Pham T; Sadowski MC; Li H; Richard DJ; d'Emden MC; Richard K
    Exp Hematol Oncol; 2015; 5():15. PubMed ID: 27340608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP17 inhibitors in prostate cancer: latest evidence and clinical potential.
    Alex AB; Pal SK; Agarwal N
    Ther Adv Med Oncol; 2016 Jul; 8(4):267-75. PubMed ID: 27482286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging novel therapies for advanced prostate cancer.
    Osanto S; Van Poppel H
    Ther Adv Urol; 2012 Feb; 4(1):3-12. PubMed ID: 22295041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging molecularly targeted therapies in castration refractory prostate cancer.
    Patel JC; Maughan BL; Agarwal AM; Batten JA; Zhang TY; Agarwal N
    Prostate Cancer; 2013; 2013():981684. PubMed ID: 23819055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
    Bambury RM; Rathkopf DE
    Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.
    Attard G; de Bono JS
    Clin Cancer Res; 2011 Jun; 17(12):3867-75. PubMed ID: 21680542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.